Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
    Investing Articles

    I wish I’d known about this profitable stock market investing strategy 10 years ago

    | Mark David Hartley

    Long-term data suggests this investment approach yields returns that surpass the performance of major stock market indexes.

    Read more »

    Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
    Investing Articles

    2 of my favourite FTSE 100 shares have just plunged 12% and 10%! Time to buy?

    | Harvey Jones

    Harvey Jones is in bargain-hunting mode and wondering if these two FTSE 100 shares could make exciting purchases after falling…

    Read more »

    Abstract bull climbing indicators on stock chart
    Investing Articles

    As AstraZeneca’s share price drops 13% should I buy on the dip?

    | Simon Watkins

    AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and earnings…

    Read more »

    Young woman holding up three fingers
    Investing Articles

    3 stunning FTSE 100 shares I plan to buy in October 

    | Mark David Hartley

    Our writer identifies three stocks on the FTSE 100 he feels would add the variety of growth, income and stability…

    Read more »

    Investing Articles

    This UK stock looks pretty cheap to me

    | Gordon Best

    This Fool is always on the hunt for value, and with plenty of potential for growth, this UK stock ticks…

    Read more »

    Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower
    Investing Articles

    My favourite UK share on the entire LSE has fallen 5% in a week! Time to buy?

    | Harvey Jones

    Harvey Jones has waited for years to buy this brilliant UK share. Has the recent stock market dip finally handed…

    Read more »

    Investing Articles

    FTSE 100 investors should pay attention to these 4 things in September 2024

    | Charlie Carman

    Charlie Carman explores four key factors for UK investors to monitor this month that will influence the future direction of…

    Read more »

    Investing Articles

    4 stocks that might power the FTSE 100 towards 10,000

    | John Fieldsend

    The FTSE 100 has been flirting with its all-time high again. Could it break through and hit that magical 10,000…

    Read more »

    Investing Articles

    As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider?

    | Ben McPoland

    Ben McPoland takes a look at the largest UK stock by market cap to assess whether it might be overvalued…

    Read more »

    Silhouette of a bull standing on top of a landscape with the sun setting behind it
    Investing Articles

    5 FTSE stocks Fools think will lead the next bull market charge

    | The Motley Fool Staff

    Savvy Fools will know the time to be buying the best FTSE stocks isn’t when a new bull market is…

    Read more »

    Person holding magnifying glass over important document, reading the small print
    Investing Articles

    Up 38% from its 12-month low, how can AstraZeneca’s share price still look cheap?

    | Simon Watkins

    Despite its big rise over the year, AstraZeneca’s share price still looks very undervalued to me, supported by strong H1…

    Read more »

    Investing Articles

    AstraZeneca hits £200bn as its share price soars. Can I afford to miss out?

    | Alan Oscroft

    The AstraZeneca share price is up 17% so far this year. But now the firm has broken the £200bn barrier,…

    Read more »